From a molecular medicinal viewpoint, Relafen 750 (naproxen sodium) signifies a compelling case study in noncopyrightal anti-inflammatory agent action. Its mode of reducing inflammation and soreness copyrights primarily on the inhibition of cyclooxygenase (COX) enzymes , specifically COX-1 and COX-2. Examining the selective aspects of this interact